Venous thromboembolism risk in cancer patients receiving first‐line immune checkpoint inhibitor versus chemotherapy
Authors:
- 10 May 2023
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 98 (8) , 1214-1222
Abstract
It remains unclear if immune checkpoint inhibitor (ICI) therapy is associated with higher rate of venous thromboembolism (VTE) compared with cytotoxic chemotherapy (chemo) in patients with comparable cancer type, staging, and comorbidities. Using the national Veterans Affairs healthcare system database from 2016 to 2021, we performed a propensity score (PS)‐weighted retrospective cohort study to compare the incidence of VTE in patients with selected stage III/IV cancer receiving first‐line ICI versus chemo. The PS model utilized overlap weights to balance age, sex, race, treatment year, VTE history, paralysis/immobilization, prolonged hospitalization, cancer type, staging, time between diagnosis and treatment, and National Cancer Institute comorbidity index. Weighted Cox regressions with robust standard error were used to assess the hazard ratio (HR) and 95% confidence interval (CI). We found that among comparable advanced cancers, first‐line ICI (n = 1823) and first‐line chemo (n = 6345) had similar rates of VTE (8.49% for ICI and 8.36% for chemo at 6 months). The weighted HR was 1.06 (95% CI 0.88–1.26) for ICI versus chemo. In a subgroup analysis restricted to lung cancers, first‐line ICI/chemo (n = 828), ICI monotherapy (n = 428), and chemo monotherapy (n = 4371) had similar rates of VTE (9.60% for ICI/chemo, 10.04% for ICI, and 8.91% for chemo at 6 months). The weighted HR was 1.05 (95% CI 0.77–1.42) for ICI versus chemo, and 1.08 (95% CI 0.83–1.42) for ICI/chemo versus chemo. In conclusion, ICI as a systemic therapy has a similarly elevated risk as cytotoxic chemo for VTE occurrence in cancer patients. This finding can inform future prospective studies exploring thromboprophylaxis strategies.Keywords
Funding Information
- American Heart Association (857078)
- Cancer Prevention and Research Institute of Texas (RR190079, RR190104)
- National Heart, Lung, and Blood Institute (K23 HL159271)
This publication has 23 references indexed in Scilit:
- Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapyBlood, 2021
- First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future ProgressFrontiers in Pharmacology, 2020
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2020
- Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective studyEuropean Journal of Cancer, 2019
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- Balancing Covariates via Propensity Score WeightingJournal of the American Statistical Association, 2017
- Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysisStatistics in Medicine, 2016
- The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experimentsStatistics in Medicine, 2013
- Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysisJournal of Thrombosis and Haemostasis, 2012
- Do Instrumental Variables Belong in Propensity Scores?2007